이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Gilead Sciences 관리

관리 기준 확인 3/4

Gilead Sciences' CEO는 Dan O'Day, Mar2019 에 임명되었습니다 의 임기는 5.25 년입니다. 총 연간 보상은 $ 22.61M, 7.7% 로 구성됩니다. 7.7% 급여 및 92.3% 보너스(회사 주식 및 옵션 포함). 는 $ 30.97M 가치에 해당하는 회사 주식의 0.039% 직접 소유합니다. 30.97M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 6.1 년입니다.

주요 정보

Dan O'Day

최고 경영자

US$22.6m

총 보상

CEO 급여 비율	7.7%
CEO 임기	5.3yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	6.1yrs

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Recent updates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Jun 13

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

May 23

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17

CEO 보상 분석

Dan O'Day 의 보수는 Gilead Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

보상 대 시장: Dan 의 총 보상 ($USD 22.61M )은 US 시장( $USD 13.50M ).

보상과 수익: Dan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dan O'Day (60 yo)

5.3yrs

테뉴어

US$22,607,690

보상

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

리더십 팀

이름	위치	테뉴어	보상	소유권
Daniel P. O'Day	Chairman & CEO	5.3yrs	US$22.61m	0.039% $ 31.0m
Andrew Dickinson	Chief Financial Officer	4.6yrs	US$8.11m	0.011% $ 8.6m
Deborah Telman	Executive VP of Corporate Affairs	1.8yrs	US$5.27m	0.0012% $ 920.5k
Johanna Mercier	Chief Commercial Officer	4.9yrs	US$8.59m	0.0097% $ 7.6m
Merdad Parsey	Chief Medical Officer	4.6yrs	US$8.39m	0.0079% $ 6.2m
Sandra Patterson	Senior VP	1.3yrs	데이터 없음	0.0027% $ 2.1m
Jacquie Ross	Vice President of Investor Relations	3.4yrs	데이터 없음	데이터 없음
Jyoti Mehra	Executive Vice President of Human Resources	4.8yrs	데이터 없음	데이터 없음
Linda Higgins	Senior Vice President of Research	4.3yrs	데이터 없음	데이터 없음
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	데이터 없음	데이터 없음
Flavius Martin	Executive Vice President of Research	3.2yrs	데이터 없음	데이터 없음
William Grossman	Senior Vice President & Therapeutic Area Head of Gilead Oncology	2.9yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: GILD 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Daniel P. O'Day	Chairman & CEO	5.3yrs	US$22.61m	0.039% $ 31.0m
Anthony Welters	Lead Independent Director	3.7yrs	US$444.92k	0.00082% $ 645.1k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	데이터 없음
Jacqueline Barton	Independent Director	6.4yrs	US$429.92k	0.0020% $ 1.5m
Eugene Schiff	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Schooley	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Harish Manwani	Independent Director	6.1yrs	US$414.92k	0.0010% $ 810.4k
John Mellors	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Francis Chisari	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Paul Klotman	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kelly Kramer	Independent Director	7.8yrs	US$434.92k	0.00011% $ 86.5k
Joel Huff	Chairperson of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.1yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: GILD 의 이사회는 경험(평균 재직 기간 6.1 년)으로 간주됩니다.

Gilead Sciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Recent updates

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences: Cheap For A Reason

Fourth quarter dividend increased to US$0.77

Full year 2023 earnings: EPS misses analyst expectations

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences: The Sky Is Not Falling

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령